COVID Off-Label is a public education project of The MedInsight Institute. We are a 501(c)(3) non-profit organization with a mission of saving lives and easing suffering through educating about new treatment options using well-established, unpromoted, low-cost generic drugs.
Through COVID Off-Label, we aim to educate the public and physicians about safe, low-cost, accessible treatment choices for COVID-19 and Long-COVID.
As a non-profit organization, we rely solely on the generosity of our donors to create and maintain the information provided on this site. Please support our efforts by making a tax-deductible donation below or join our efforts in other ways.
Our Advisory Board
Our Advisory Board brings together global thought leaders and prominent activists in the fields of medicine, drug research, public health, health equity, and social impact.
Moshe Rogosnitzky Editor - COVID Off-Label
Moshe Rogosnitzky is an internationally recognized expert in drug repurposing. Moshe’s new drug-use discoveries have led to the repurposing of drugs for treating Crohn’s disease, cancers of the breast, prostate, skin, liver, pancreas, thymus; pain conditions, insomnia, viral infections, wound bleeding, xerostomia, pterygium, pinguecula, melanocytic nevus, corneal neovascularization, dry eye disease, and COVID-19. Moshe has lectured about drug repurposing at MIT (Cambridge, MA), Charite Medical University (Berlin), the Israeli Ministry of Health, and Tel Aviv University. He has published over 30 papers in the medical literature on a broad range of topics. He most recently contributed a book chapter named “Field Discoveries (Case Reports)” to the Royal Society of Chemistry’s seminal book on Drug Repurposing. Moshe is co-founder of the MedInsight Research Institute – a nonprofit organization focused on expanding treatment options for patients through education about off-label uses of safe generic drugs. LDNscience.org, a MedInsight project, serves as an information and educational portal for low dose naltrexone (LDN), a project that has evolved to become the largest patient-driven drug repurposing project in history. COVID Off-Label is a MedInsight educational initiative.
Venkata Mahidhar Yenugonda, M.Phil, Ph.D, FNAI
Dr. Yenugonda is an accomplished medicinal chemistry research professional with an impressive track record of delivering small molecule drug candidates across numerous therapeutic areas. He is the director of the Translational Experimental Therapeutics Research Program at the Saint John’s Cancer Institute, an affiliated Translational Scientist at the Pacific Neuroscience Institute, and an adjunct assistant professor at the Georgetown Lombardi Cancer Center. Dr. Yenugonda holds a master’s degree in organic chemistry and a Ph.D. in Medical Chemistry from the Indian Institute of Chemical Technology. A leader in translational research, he has formed strategic collaborations with pharma/biopharma partnerships on small molecule discovery projects. Several of his novel agents are licensed for commercial development. Dr. Yenugonda is the recipient of multiple awards for his contributions to chemical research. He is a member of the National Academy of Inventors, the American Association of Cancer Research, Society for Neuroscience, and Society for Neuro-Oncology.
Bartley J. Madden
Bartley J. Madden is an independent researcher. He retired as a managing director of Credit Suisse HOLT after a career in investment research and money management that included the founding of Callard Madden & Associates. His early research was instrumental in the development of the cash-flow return on investment (CFROI) life-cycle valuation framework that is used today by money management firms worldwide. Over the last two decades, he has published journal articles and books across different disciplines as reflected in these recent books: Value Creation Principles and A Foundational Explanation of Human Behavior. An early version of his book, Free To Choose Medicine: Better Drugs Sooner at Lower Cost, was translated into Japanese and played a significant role in Japan’s implementation of their version of Free To Choose Medicine to facilitate early, informed access to regenerative medicine drugs, see www.freetochoosemedicine.com.